Mannitol 10g/400ml (2.5%) infusion bags
Requires a prescription from a doctor or prescriber
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Mannitol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Mannitol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Cystic fibrosis: diagnosis and management (NG78)
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 16 · Randomised trials: 8 · 1967–2026
Showing the 50 most relevant studies, sorted by most relevant.
Hooman Kamel, Babak B. Navi, Kazuma Nakagawa, et al.
Critical Care Medicine, 2011
- Diuretics, Osmotic
- Intracranial Pressure
- Mannitol
Claire Battison, P. Andrews, C. Graham, et al.
Critical Care Medicine, 2005
- Blood Pressure
- Brain
- Brain Edema
Joseph T. Santoso, Joseph A. Lucci, Robert L. Coleman, et al.
Cancer Chemotherapy and Pharmacology, 2003
- Antiemetics
- Antineoplastic Agents
- Cisplatin
Takshay Patel, John D. Williamson
Trends in Plant Science, 2016
- Fungi
- Mannitol
- Mannitol Dehydrogenases
Jiajie Gu, Haoping Huang, Yuejun Huang, et al.
Neurosurgical Review, 2018
Diana Bilton, Gregory Tino, Alan F. Barker, et al.
Thorax, 2014
- Administration, Inhalation
- Anti-Bacterial Agents
- Bronchiectasis
Sarah V Burgess, R. Abu-Laban, R. Slavik, et al.
Annals of Pharmacotherapy, 2016
Kao CC, Tai HY, Sio YC, et al.
2025
- Cisplatin
- Mannitol
- Antineoplastic Agents
Alsabri M, Rath S, Mahmoud YA, et al.
2026
- Mannitol
- Diuretics, Osmotic
- Brain Injuries, Traumatic
Afridi A, Bacha Z, Sajjad F, et al.
2025
- Intracranial Hypertension
- Mannitol
- Diuretics, Osmotic
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
221 found
Half-life
4.7 hours
Mechanism
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
7%
Inhalation…
Half-life
4.7 hours
Volume of distribution
34.3 L
[L20024]
Metabolism
Elimination
635 mg
Clearance
5.1 L/h
[L20024]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chiesi USA Inc.[L20024]
Mannitol is also indicated as add-on maintenance therapy for improving pulmonary function in cystic fibrosis patients aged 18 and over who have passed the BRONCHITOL tolerance test (BTT). It is recommended that patients take an orally inhaled short-acting bronchodilator 5-15 minutes prior to every inhaled mannitol dose.
[L20024]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1345 interactions
[L20024]
The exact mechanism of action of inhaled mannitol in the symptomatic maintenance treatment of cystic fibrosis remains unclear.[A223199][L20024] It is hypothesized that mannitol produces an osmotic gradient across the airway epithelium that draws fluid into the extracellular space and alters the properties of the airway surface mucus layer, allowing easier mucociliary clearance.[A223199]
Inhaled mannitol has the possibility to cause bronchospasm and hemoptysis; the occurrence of either should lead to discontinuation of inhaled mannitol.[L20024]
How the body processes this drug — absorption, distribution, metabolism, and elimination
Inhalation of 635 mg of mannitol powder yields a plasma Cmax of 13.71 μg/mL in 1.5 hours (Tmax) and a mean systemic AUC of 73.15 μg\*h/mL.
[L20024]
[L20024]
[L20024]
[L20024]
[L20024]
ATC B05CX04
ATC A06AD16
ATC R05CB16
ATC B05BC01
ATC V04CX04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Mannitol
Additional database identifiers
Drugs Product Database (DPD)
9547
ChemSpider
6015
BindingDB
50142798
PDB
MTL
ZINC
ZINC000002041302
GenBank Gene Database
AF007800
UniProt Accession
O08355_PSEFL
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q407646), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.